Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ocular Therapeutix, Inc.

Criteria

Inclusion Criteria:

• Dry eye disease diagnosis

• VAS eye dryness severity score ≥ 30.

Exclusion Criteria:

• Are unwilling to discontinue use of contact lenses

• Are unwilling to withhold use of artificial tears.